CoChat

CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration

Open access
Burnight, Erin R., Giacalone, Joseph C., Cooke, Jessica A., Thompson, Jessica R., Bohrer, Laura R., Chirco, Kathleen R., Drack, Arlene V., Fingert, John H., Worthington, Kristan S., Wiley, Luke A., Mullins, Robert F., Stone, Edwin M., Tucker, Budd A. · 2018 · Progress in Retinal and Eye Research
Cited by 74

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

&NA; Gene correction is a valuable strategy for treating inherited retinal degenerative diseases, a major cause of irreversible blindness worldwide. Single gene defects cause the majority of these retinal dystrophies. Gene augmentation holds great promise if delivered early in the course of the disease, however, many patients carry mutations in genes too large to be packaged into adeno‐associated viral vectors and some, when overexpressed via heterologous promoters, induce retinal toxicity. In addition to the aforementioned challenges, some patients have sustained significant photoreceptor cell loss at the time of diagnosis, rendering gene replacement therapy insufficient to treat the disease. These patients will require cell replacement to restore useful vision. Fortunately, the advent of induced pluripotent stem cell and CRISPR‐Cas9 gene editing technologies affords researchers and clinicians a powerful means by which to develop strategies to treat patients with inherited retinal dystrophies. In this review we will discuss the current developments in CRISPR‐Cas9 gene editing in vivo in animal models and in vitro in patient‐derived cells to study and treat inherited retinal degenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.preteyeres.2018.03.003

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 74

Metadata

Authors
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., Mullins, R. F., Stone, E. M., & Tucker, B. A.
Venue
Progress in Retinal and Eye Research
Publisher
Elsevier BV
Published
2018-07
Volume
65
Pages
28-49
ISSN
1350-9462 (ISSN-L)
OpenAlex
W2789344364
Cited by
74
References
60
FWCI
3.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration. https://app.cochat.ai/papers/10.1016/j.preteyeres.2018.03.003
The paper
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., Mullins, R. F., Stone, E. M., & Tucker, B. A. (2018). CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration. Progress in Retinal and Eye Research. https://doi.org/10.1016/j.preteyeres.2018.03.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.